By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Foundation Medicine's today said that its genomic tests will be used by biopharmaceutical company Celgene for clinical trials of its anti-cancer drug candidates.

Foundation's test, which is under development, will be used to hasten faster recruitment of target patient populations and for broad genetic characterization of trial enrollees in order to identify patients most likely to respond to Celgene's drug candidates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.